drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB04837 | DB06016 | 649 | 1,508 | [
"DDInter407",
"DDInter300"
] | Clofedanol | Cariprazine | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
649,
24,
1508
]
],
[
[
649,
63,
1242
],
[
1242,
24,
1508
]
],
[
[
649,
1,
832
],
[
832,
24,
1508
]
],
[
[
649,
24,
849
],
[
849,
... | [
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
... | Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Clofedanol (Compound) resembles Tripelennamine (Compound) and Tripelennamine may cause a moderate interaction t... |
DB00041 | DB00612 | 1,648 | 1,121 | [
"DDInter38",
"DDInter216"
] | Aldesleukin | Bisoprolol | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Moderate | 1 | [
[
[
1648,
24,
1121
]
],
[
[
1648,
24,
819
],
[
819,
40,
1121
]
],
[
[
1648,
24,
251
],
[
251,
24,
1121
]
],
[
[
1648,
24,
1211
],
[
1211,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisoprolol"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Bisoprolol (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction th... |
DB00792 | DB04948 | 832 | 1,084 | [
"DDInter1878",
"DDInter1083"
] | Tripelennamine | Lofexidine | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
832,
24,
1084
]
],
[
[
832,
24,
1617
],
[
1617,
1,
1084
]
],
[
[
832,
63,
1020
],
[
1020,
1,
1084
]
],
[
[
832,
24,
1311
],
[
1311,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine (Compound) resembles Lofexidine... |
DB01377 | DB08912 | 1,283 | 1,040 | [
"DDInter1119",
"DDInter462"
] | Magnesium oxide | Dabrafenib | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1283,
24,
1040
]
],
[
[
1283,
24,
478
],
[
478,
24,
1040
]
],
[
[
1283,
62,
870
],
[
870,
24,
1040
]
],
[
[
1283,
23,
481
],
[
481,
... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],... | Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone... |
DB00622 | DB09340 | 1,081 | 1,013 | [
"DDInter1287",
"DDInter1895"
] | Nicardipine | Tyropanoic acid | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Moderate | 1 | [
[
[
1081,
24,
1013
]
],
[
[
1081,
40,
409
],
[
409,
24,
1013
]
],
[
[
1081,
24,
1431
],
[
1431,
24,
1013
]
],
[
[
1081,
63,
1648
],
[
1648... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a ... | Nicardipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Gadopentetic acid and Gadopentetic acid may cause a moderate i... |
DB00757 | DB04946 | 1,166 | 924 | [
"DDInter581",
"DDInter907"
] | Dolasetron | Iloperidone | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
1166,
25,
924
]
],
[
[
1166,
64,
1664
],
[
1664,
1,
924
]
],
[
[
1166,
64,
1425
],
[
1425,
25,
924
]
],
[
[
1166,
25,
519
],
[
519,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risperidone"
],
[
"Risperidone",
"{u... | Dolasetron may lead to a major life threatening interaction when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Iloperi... |
DB00418 | DB06589 | 536 | 1,250 | [
"DDInter1650",
"DDInter1400"
] | Secobarbital | Pazopanib | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
536,
24,
1250
]
],
[
[
536,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
536,
21,
28658
],
[
28658,
60,
1250
]
],
[
[
536,
24,
112
],
[
112,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Secobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound... | Secobarbital (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Secobarbital (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and... |
DB00215 | DB06754 | 1,230 | 707 | [
"DDInter388",
"DDInter471"
] | Citalopram | Danaparoid | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Moderate | 1 | [
[
[
1230,
24,
707
]
],
[
[
1230,
25,
121
],
[
121,
24,
707
]
],
[
[
1230,
1,
318
],
[
318,
24,
707
]
],
[
[
1230,
24,
235
],
[
235,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danaparoid"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
],
[
"Fenflura... | Citalopram may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Citalopram (Compound) resembles Escitalopram (Compound) and Es
Citalopram may cause a moderate interaction that could exace... |
DB00526 | DB12674 | 1,555 | 975 | [
"DDInter1355",
"DDInter1105"
] | Oxaliplatin | Lurbinectedin | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
1555,
24,
975
]
],
[
[
1555,
24,
1488
],
[
1488,
24,
975
]
],
[
[
1555,
63,
589
],
[
589,
24,
975
]
],
[
[
1555,
25,
868
],
[
868,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and ... |
DB00284 | DB01365 | 1,647 | 280 | [
"DDInter11",
"DDInter1151"
] | Acarbose | Mephentermine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Moderate | 1 | [
[
[
1647,
24,
280
]
],
[
[
1647,
24,
1445
],
[
1445,
1,
280
]
],
[
[
1647,
24,
22
],
[
22,
40,
280
]
],
[
[
1647,
24,
1466
],
[
1466,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Mephentermine (Compound)
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Mephentermine (... |
DB00757 | DB04896 | 1,166 | 901 | [
"DDInter581",
"DDInter1220"
] | Dolasetron | Milnacipran | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Major | 2 | [
[
[
1166,
25,
901
]
],
[
[
1166,
25,
41
],
[
41,
1,
901
]
],
[
[
1166,
64,
1349
],
[
1349,
40,
901
]
],
[
[
1166,
21,
28786
],
[
28786,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
... | Dolasetron may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Milnacipran (Compound)
Dolasetron (Compou... |
DB00852 | DB04896 | 1,445 | 901 | [
"DDInter1545",
"DDInter1220"
] | Pseudoephedrine | Milnacipran | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Moderate | 1 | [
[
[
1445,
24,
901
]
],
[
[
1445,
24,
41
],
[
41,
1,
901
]
],
[
[
1445,
6,
6112
],
[
6112,
45,
901
]
],
[
[
1445,
21,
28786
],
[
28786,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Pseudoephedrine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Milnacipran (Compound)
Pseudoephedrine (Compound) causes Urinary re... |
DB01211 | DB09075 | 609 | 498 | [
"DDInter393",
"DDInter621"
] | Clarithromycin | Edoxaban | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
609,
25,
498
]
],
[
[
609,
25,
41
],
[
41,
24,
498
]
],
[
[
609,
63,
311
],
[
311,
24,
498
]
],
[
[
609,
25,
321
],
[
321,
63,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipra... | Clarithromycin may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib and Valde... |
DB00603 | DB00615 | 303 | 690 | [
"DDInter1137",
"DDInter1589"
] | Medroxyprogesterone acetate | Rifabutin | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Moderate | 1 | [
[
[
303,
24,
690
]
],
[
[
303,
24,
463
],
[
463,
1,
690
]
],
[
[
303,
6,
8374
],
[
8374,
45,
690
]
],
[
[
303,
21,
28996
],
[
28996,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound)
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound)
Medroxyprogesterone acetate (Compo... |
DB06077 | DB11963 | 879 | 1,045 | [
"DDInter1102",
"DDInter465"
] | Lumateperone | Dacomitinib | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Moderate | 1 | [
[
[
879,
24,
1045
]
],
[
[
879,
63,
1376
],
[
1376,
24,
1045
]
],
[
[
879,
25,
384
],
[
384,
24,
1045
]
],
[
[
879,
64,
1311
],
[
1311,
... | [
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]... | Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Lumateperone may lead to a major life threatening interaction when taken with Idelalisib and Idelal... |
DB00476 | DB09074 | 109 | 1,362 | [
"DDInter608",
"DDInter1327"
] | Duloxetine | Olaparib | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
109,
24,
1362
]
],
[
[
109,
63,
1684
],
[
1684,
24,
1362
]
],
[
[
109,
24,
1619
],
[
1619,
63,
1362
]
],
[
[
109,
24,
1468
],
[
1468,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caffeine"
],
[
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Caffeine and Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may... |
DB08826 | DB13257 | 1,292 | 260 | [
"DDInter489",
"DDInter727"
] | Deferiprone | Ferrous sulfate anhydrous | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age. This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. Ferrous sulfate is a sy... | Moderate | 1 | [
[
[
1292,
24,
260
]
],
[
[
1292,
24,
1114
],
[
1114,
23,
260
]
],
[
[
1292,
64,
1096
],
[
1096,
23,
260
]
],
[
[
1292,
24,
460
],
[
460,
... | [
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfa... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ferrous sulfate anhydrous
Deferiprone may lead to a major life threatening interaction when taken with Mycophenolic acid... |
DB00459 | DB00631 | 640 | 372 | [
"DDInter21",
"DDInter405"
] | Acitretin | Clofarabine | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
640,
24,
372
]
],
[
[
640,
7,
10861
],
[
10861,
46,
372
]
],
[
[
640,
21,
28903
],
[
28903,
60,
372
]
],
[
[
640,
63,
1560
],
[
1560,
... | [
[
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Acitretin",
"{u} (Compound) upregulates {v} (Gene)",
"KCTD5"
],
[
"KCTD5",
"{u} (Gene) is upregulated by {v} (Co... | Acitretin (Compound) upregulates KCTD5 (Gene) and KCTD5 (Gene) is upregulated by Clofarabine (Compound)
Acitretin (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Clofarabine (Compound)
Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase... |
DB01070 | DB12147 | 1,098 | 241 | [
"DDInter558",
"DDInter661"
] | Dihydrotachysterol | Erdafitinib | A vitamin D that can be regarded as a reduction product of vitamin D2. | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Major | 2 | [
[
[
1098,
25,
241
]
],
[
[
1098,
24,
286
],
[
286,
25,
241
]
],
[
[
1098,
63,
965
],
[
965,
25,
241
]
],
[
[
1098,
25,
1196
],
[
1196,
... | [
[
[
"Dihydrotachysterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Dihydrotachysterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
... | Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Erdafitinib
Dihydrotachysterol may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB01155 | DB09043 | 872 | 135 | [
"DDInter813",
"DDInter36"
] | Gemifloxacin | Albiglutide | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
872,
24,
135
]
],
[
[
872,
64,
126
],
[
126,
23,
135
]
],
[
[
872,
63,
1647
],
[
1647,
23,
135
]
],
[
[
872,
40,
739
],
[
739,
2... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfari... | Gemifloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a min... |
DB00206 | DB06691 | 1,245 | 849 | [
"DDInter1582",
"DDInter1155"
] | Reserpine | Mepyramine | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1245,
24,
849
]
],
[
[
1245,
7,
2216
],
[
2216,
46,
849
]
],
[
[
1245,
24,
770
],
[
770,
24,
849
]
],
[
[
1245,
63,
1648
],
[
1648,
... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Reserpine",
"{u} (Compound) upregulates {v} (Gene)",
"PAK1"
],
[
"PAK1",
"{u} (Gene) is upregulated by {v} (Compo... | Reserpine (Compound) upregulates PAK1 (Gene) and PAK1 (Gene) is upregulated by Mepyramine (Compound)
Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Reserpine ... |
DB00734 | DB11718 | 1,664 | 927 | [
"DDInter1605",
"DDInter640"
] | Risperidone | Encorafenib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1664,
24,
927
]
],
[
[
1664,
23,
112
],
[
112,
23,
927
]
],
[
[
1664,
24,
720
],
[
720,
24,
927
]
],
[
[
1664,
63,
1324
],
[
1324,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and ... |
DB00682 | DB01416 | 126 | 1,024 | [
"DDInter1951",
"DDInter326"
] | Warfarin | Cefpodoxime | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. | Moderate | 1 | [
[
[
126,
24,
1024
]
],
[
[
126,
24,
1453
],
[
1453,
1,
1024
]
],
[
[
126,
63,
149
],
[
149,
40,
1024
]
],
[
[
126,
24,
665
],
[
665,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefpodoxime"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftriaxone"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ceftriaxone and Ceftriaxone (Compound) resembles Cefpodoxime (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Cefpodoxime (Compound... |
DB11569 | DB11627 | 1,093 | 1,367 | [
"DDInter1003",
"DDInter860"
] | Ixekizumab | Hepatitis B Vaccine (Recombinant) | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
1093,
24,
1367
]
],
[
[
1093,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
1093,
63,
259
],
[
259,
24,
1367
]
],
[
[
1093,
24,
1456
],
[
1456... | [
[
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Ixekizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
... | Ixekizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept an... |
DB09049 | DB11986 | 1,135 | 484 | [
"DDInter1261",
"DDInter648"
] | Naloxegol | Entrectinib | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Minor | 0 | [
[
[
1135,
23,
484
]
],
[
[
1135,
63,
998
],
[
998,
24,
484
]
],
[
[
1135,
62,
1072
],
[
1072,
24,
484
]
],
[
[
1135,
24,
1320
],
[
1320,
... | [
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
],
[
... | Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Isoniazid and Is... |
DB01232 | DB11113 | 1,327 | 657 | [
"DDInter1640",
"DDInter307"
] | Saquinavir | Castor oil | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1327,
24,
657
]
],
[
[
1327,
25,
927
],
[
927,
63,
657
]
],
[
[
1327,
25,
1491
],
[
1491,
24,
657
]
],
[
[
1327,
63,
891
],
[
891,
... | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafen... | Saquinavir may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Saquinavir may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate ... |
DB00655 | DB00673 | 559 | 723 | [
"DDInter682",
"DDInter112"
] | Estrone | Aprepitant | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
559,
24,
723
]
],
[
[
559,
6,
7950
],
[
7950,
45,
723
]
],
[
[
559,
10,
11579
],
[
11579,
49,
723
]
],
[
[
559,
21,
28890
],
[
28890,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Estrone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Estrone (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is palliated by Aprepitant (Compound)
Estrone (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is cause... |
DB00762 | DB11793 | 613 | 738 | [
"DDInter973",
"DDInter1297"
] | Irinotecan | Niraparib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
613,
24,
738
]
],
[
[
613,
24,
466
],
[
466,
63,
738
]
],
[
[
613,
24,
1213
],
[
1213,
24,
738
]
],
[
[
613,
63,
1253
],
[
1253,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasa... |
DB00250 | DB08820 | 10 | 1,478 | [
"DDInter475",
"DDInter997"
] | Dapsone | Ivacaftor | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
10,
24,
1478
]
],
[
[
10,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
10,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
10,
23,
307
],
[
307,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Dapsone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Dapsone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Dapsone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause ... |
DB00814 | DB01172 | 1,171 | 416 | [
"DDInter1143",
"DDInter1004"
] | Meloxicam | Kanamycin | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
1171,
24,
416
]
],
[
[
1171,
6,
7720
],
[
7720,
46,
416
]
],
[
[
1171,
21,
29196
],
[
29196,
60,
416
]
],
[
[
1171,
24,
712
],
[
712,
... | [
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Meloxicam",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)"... | Meloxicam (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Meloxicam (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Kanamycin (Compound)
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and... |
DB00457 | DB01168 | 1,205 | 1,053 | [
"DDInter1511",
"DDInter1526"
] | Prazosin | Procarbazine | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTS... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1205,
24,
1053
]
],
[
[
1205,
24,
848
],
[
848,
40,
1053
]
],
[
[
1205,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1205,
24,
104
],
[
104... | [
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Prazosin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Prazosin may cause a moderate interaction that c... |
DB00019 | DB00444 | 1,257 | 63 | [
"DDInter1405",
"DDInter1765"
] | Pegfilgrastim | Teniposide | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Moderate | 1 | [
[
[
1257,
24,
63
]
],
[
[
1257,
24,
147
],
[
147,
62,
63
]
],
[
[
1257,
24,
738
],
[
738,
63,
63
]
],
[
[
1257,
24,
599
],
[
599,
24... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Teniposide
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and N... |
DB00196 | DB00445 | 600 | 322 | [
"DDInter743",
"DDInter655"
] | Fluconazole | Epirubicin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
600,
24,
322
]
],
[
[
600,
7,
14690
],
[
14690,
46,
322
]
],
[
[
600,
7,
7885
],
[
7885,
57,
322
]
],
[
[
600,
18,
7847
],
[
7847,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Fluconazole",
"{u} (Compound) upregulates {v} (Gene)",
"ABHD6"
],
[
"ABHD6",
"{u} (Gene) is upregulated by {v} ... | Fluconazole (Compound) upregulates ABHD6 (Gene) and ABHD6 (Gene) is upregulated by Epirubicin (Compound)
Fluconazole (Compound) upregulates MELK (Gene) and MELK (Gene) is downregulated by Epirubicin (Compound)
Fluconazole (Compound) downregulates BAG3 (Gene) and BAG3 (Gene) is downregulated by Epirubicin (Compound)
Flu... |
DB01159 | DB14723 | 419 | 159 | [
"DDInter854",
"DDInter1026"
] | Halothane | Larotrectinib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
419,
24,
159
]
],
[
[
419,
24,
98
],
[
98,
24,
159
]
],
[
[
419,
63,
1181
],
[
1181,
24,
159
]
],
[
[
419,
64,
11
],
[
11,
24,
... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
... | Halothane may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenad... |
DB01001 | DB01242 | 688 | 1,237 | [
"DDInter1632",
"DDInter410"
] | Salbutamol | Clomipramine | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
688,
24,
1237
]
],
[
[
688,
63,
684
],
[
684,
1,
1237
]
],
[
[
688,
24,
401
],
[
401,
24,
1237
]
],
[
[
688,
24,
9
],
[
9,
1,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction ... |
DB01234 | DB09083 | 1,220 | 880 | [
"DDInter513",
"DDInter996"
] | Dexamethasone | Ivabradine | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Moderate | 1 | [
[
[
1220,
24,
880
]
],
[
[
1220,
62,
480
],
[
480,
24,
880
]
],
[
[
1220,
24,
1478
],
[
1478,
24,
880
]
],
[
[
1220,
24,
159
],
[
159,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Formoterol"
],
... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Iva... |
DB00381 | DB09038 | 376 | 1,450 | [
"DDInter79",
"DDInter636"
] | Amlodipine | Empagliflozin | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
376,
24,
1450
]
],
[
[
376,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
376,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
376,
40,
84
],
[
84,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Methylpredniso... |
DB00283 | DB00780 | 701 | 551 | [
"DDInter395",
"DDInter1440"
] | Clemastine | Phenelzine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Moderate | 1 | [
[
[
701,
24,
551
]
],
[
[
701,
24,
94
],
[
94,
40,
551
]
],
[
[
701,
6,
8374
],
[
8374,
45,
551
]
],
[
[
701,
21,
28722
],
[
28722,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenacemide"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phenacemide and Phenacemide (Compound) resembles Phenelzine (Compound)
Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Phenelzine (Compound)
Clemastine (Compound) causes Nausea (Side Effect) and Nausea (Si... |
DB00197 | DB01268 | 1,324 | 1,151 | [
"DDInter1881",
"DDInter1731"
] | Troglitazone | Sunitinib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1324,
24,
1151
]
],
[
[
1324,
24,
655
],
[
655,
63,
1151
]
],
[
[
1324,
24,
1148
],
[
1148,
24,
1151
]
],
[
[
1324,
63,
1179
],
[
1179... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and I... |
DB12941 | DB13879 | 466 | 1,043 | [
"DDInter481",
"DDInter824"
] | Darolutamide | Glecaprevir | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Moderate | 1 | [
[
[
466,
24,
1043
]
],
[
[
466,
63,
353
],
[
353,
24,
1043
]
],
[
[
466,
62,
971
],
[
971,
24,
1043
]
],
[
[
466,
64,
1220
],
[
1220,
... | [
[
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
... | Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib a... |
DB01229 | DB10429 | 973 | 200 | [
"DDInter1377",
"DDInter282"
] | Paclitaxel | Candida albicans | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
973,
24,
200
]
],
[
[
973,
24,
1683
],
[
1683,
24,
200
]
],
[
[
973,
25,
976
],
[
976,
24,
200
]
],
[
[
973,
63,
168
],
[
168,
2... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Paclitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib ... |
DB00744 | DB08870 | 1,288 | 850 | [
"DDInter1962",
"DDInter228"
] | Zileuton | Brentuximab vedotin | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1288,
24,
850
]
],
[
[
1288,
63,
267
],
[
267,
24,
850
]
],
[
[
1288,
24,
1033
],
[
1033,
63,
850
]
],
[
[
1288,
24,
392
],
[
392,
... | [
[
[
"Zileuton",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Zileuton",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
... | Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Al... |
DB06081 | DB06779 | 1,046 | 365 | [
"DDInter286",
"DDInter470"
] | Caplacizumab | Dalteparin | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
1046,
25,
365
]
],
[
[
1046,
23,
539
],
[
539,
62,
365
]
],
[
[
1046,
63,
305
],
[
305,
24,
365
]
],
[
[
1046,
24,
1496
],
[
1496,
... | [
[
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Caplacizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",... | Caplacizumab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia ... |
DB00681 | DB00959 | 1,287 | 1,486 | [
"DDInter85",
"DDInter1191"
] | Amphotericin B | Methylprednisolone | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1287,
24,
1486
]
],
[
[
1287,
63,
175
],
[
175,
40,
1486
]
],
[
[
1287,
24,
167
],
[
167,
1,
1486
]
],
[
[
1287,
63,
251
],
[
251,
... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolo... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) re... |
DB00552 | DB15091 | 1,238 | 676 | [
"DDInter1425",
"DDInter1901"
] | Pentostatin | Upadacitinib | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1238,
25,
676
]
],
[
[
1238,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1238,
63,
597
],
[
597,
24,
676
]
],
[
[
1238,
63,
1184
],
[
1184,
... | [
[
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipu... | Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenic... |
DB00197 | DB08931 | 1,324 | 947 | [
"DDInter1881",
"DDInter1600"
] | Troglitazone | Riociguat | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Moderate | 1 | [
[
[
1324,
24,
947
]
],
[
[
1324,
24,
1478
],
[
1478,
24,
947
]
],
[
[
1324,
24,
124
],
[
124,
63,
947
]
],
[
[
1324,
23,
1101
],
[
1101,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasde... |
DB00697 | DB09268 | 876 | 1,662 | [
"DDInter1821",
"DDInter1464"
] | Tizanidine | Picosulfuric acid | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
876,
24,
1662
]
],
[
[
876,
24,
484
],
[
484,
63,
1662
]
],
[
[
876,
25,
1619
],
[
1619,
63,
1662
]
],
[
[
876,
25,
1618
],
[
1618,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
... | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Tizanidine may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may... |
DB01041 | DB01114 | 770 | 272 | [
"DDInter1789",
"DDInter362"
] | Thalidomide | Chlorpheniramine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
770,
24,
272
]
],
[
[
770,
24,
358
],
[
358,
63,
272
]
],
[
[
770,
63,
128
],
[
128,
24,
272
]
],
[
[
770,
6,
7524
],
[
7524,
45... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dexbromph... |
DB10344 | DB11837 | 992 | 1,297 | [
"DDInter818",
"DDInter1351"
] | Ginger | Osilodrostat | Ginger allergenic extract is used in allergenic testing. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
992,
24,
1297
]
],
[
[
992,
63,
578
],
[
578,
24,
1297
]
],
[
[
992,
24,
405
],
[
405,
24,
1297
]
],
[
[
992,
63,
1593
],
[
1593,
... | [
[
[
"Ginger",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Ginger",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"T... | Ginger may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat
Ginger may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib and Acalabrut... |
DB00661 | DB04868 | 122 | 478 | [
"DDInter1928",
"DDInter1293"
] | Verapamil | Nilotinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
122,
24,
478
]
],
[
[
122,
24,
1468
],
[
1468,
63,
478
]
],
[
[
122,
6,
6017
],
[
6017,
45,
478
]
],
[
[
122,
21,
28762
],
[
28762,
... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Verapamil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Verapamil (Compound) cau... |
DB09039 | DB11760 | 1,670 | 119 | [
"DDInter629",
"DDInter1742"
] | Eliglustat | Talazoparib | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1670,
24,
119
]
],
[
[
1670,
64,
441
],
[
441,
24,
119
]
],
[
[
1670,
25,
1339
],
[
1339,
63,
119
]
],
[
[
1670,
63,
1478
],
[
1478,
... | [
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavird... | Eliglustat may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Eliglustat may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a modera... |
DB00631 | DB00675 | 372 | 888 | [
"DDInter405",
"DDInter1744"
] | Clofarabine | Tamoxifen | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
372,
24,
888
]
],
[
[
372,
6,
17404
],
[
17404,
45,
888
]
],
[
[
372,
7,
7669
],
[
7669,
46,
888
]
],
[
[
372,
18,
13123
],
[
13123,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Clofarabine",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Clofarabine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Tamoxifen (Compound)
Clofarabine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Tamoxifen (Compound)
Clofarabine (Compound) downregulates ELOVL6 (Gene) and ELOVL6 (Gene) is upregulated by Tamoxifen (Compound)
Clofarabine (Com... |
DB01088 | DB08896 | 714 | 292 | [
"DDInter908",
"DDInter1576"
] | Iloprost | Regorafenib | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
714,
25,
292
]
],
[
[
714,
24,
549
],
[
549,
23,
292
]
],
[
[
714,
24,
643
],
[
643,
24,
292
]
],
[
[
714,
63,
109
],
[
109,
24,... | [
[
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflo... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and D... |
DB00827 | DB08907 | 646 | 1,344 | [
"DDInter383",
"DDInter280"
] | Cinoxacin | Canagliflozin | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
646,
24,
1344
]
],
[
[
646,
24,
549
],
[
549,
1,
1344
]
],
[
[
646,
21,
28681
],
[
28681,
60,
1344
]
],
[
[
646,
25,
1486
],
[
1486,
... | [
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Cinoxacin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Canagliflozin (Compound)
Cinoxacin may lead t... |
DB00196 | DB00270 | 600 | 1,428 | [
"DDInter743",
"DDInter993"
] | Fluconazole | Isradipine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Moderate | 1 | [
[
[
600,
24,
1428
]
],
[
[
600,
24,
376
],
[
376,
40,
1428
]
],
[
[
600,
24,
854
],
[
854,
1,
1428
]
],
[
[
600,
6,
8374
],
[
8374,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
],
[
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Isradipine (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine and Nimodipine (Compound) resembles Isradipine (Compound... |
DB01254 | DB05294 | 1,213 | 1,069 | [
"DDInter484",
"DDInter1917"
] | Dasatinib | Vandetanib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
1213,
25,
1069
]
],
[
[
1213,
63,
1195
],
[
1195,
40,
1069
]
],
[
[
1213,
6,
17404
],
[
17404,
45,
1069
]
],
[
[
1213,
34,
6732
],
[
6... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Dasatinib (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Vandetanib (Compound)
Dasatinib (Compound) binds MAP2K5 (Gene) and Dasatinib (Compound) upregu... |
DB00005 | DB09330 | 1,057 | 985 | [
"DDInter687",
"DDInter1352"
] | Etanercept | Osimertinib | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1057,
25,
985
]
],
[
[
1057,
25,
168
],
[
168,
23,
985
]
],
[
[
1057,
24,
112
],
[
112,
23,
985
]
],
[
[
1057,
25,
134
],
[
134,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} ... | Etanercept may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may c... |
DB00681 | DB01042 | 1,287 | 1,307 | [
"DDInter85",
"DDInter1144"
] | Amphotericin B | Melphalan | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
1287,
24,
1307
]
],
[
[
1287,
21,
28766
],
[
28766,
60,
1307
]
],
[
[
1287,
24,
1186
],
[
1186,
63,
1307
]
],
[
[
1287,
63,
663
],
[
6... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Amphotericin B",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effe... | Amphotericin B (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Melphalan (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exac... |
DB09128 | DB09268 | 1,241 | 1,662 | [
"DDInter231",
"DDInter1464"
] | Brexpiprazole | Picosulfuric acid | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1241,
24,
1662
]
],
[
[
1241,
25,
1619
],
[
1619,
63,
1662
]
],
[
[
1241,
24,
913
],
[
913,
63,
1662
]
],
[
[
1241,
63,
129
],
[
129,
... | [
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
... | Brexpiprazole may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutami... |
DB00514 | DB01148 | 506 | 1,128 | [
"DDInter527",
"DDInter738"
] | Dextromethorphan | Flavoxate | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
506,
24,
1128
]
],
[
[
506,
21,
28769
],
[
28769,
60,
1128
]
],
[
[
506,
24,
537
],
[
537,
63,
1128
]
],
[
[
506,
24,
1376
],
[
1376,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"... | Dextromethorphan (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flavoxate (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases ... |
DB01174 | DB08907 | 697 | 1,344 | [
"DDInter1442",
"DDInter280"
] | Phenobarbital | Canagliflozin | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
697,
24,
1344
]
],
[
[
697,
6,
5912
],
[
5912,
45,
1344
]
],
[
[
697,
21,
28681
],
[
28681,
60,
1344
]
],
[
[
697,
25,
1033
],
[
1033,... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Comp... | Phenobarbital (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Canagliflozin (Compound)
Phenobarbital (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Canagliflozin (Compound)
Phenobarbital may lead to a major life threatening interaction when taken with Alpelis... |
DB00041 | DB00633 | 1,648 | 614 | [
"DDInter38",
"DDInter520"
] | Aldesleukin | Dexmedetomidine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. | Moderate | 1 | [
[
[
1648,
24,
614
]
],
[
[
1648,
24,
1214
],
[
1214,
24,
614
]
],
[
[
1648,
24,
516
],
[
516,
63,
614
]
],
[
[
1648,
25,
770
],
[
770,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexmedetomidine"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Dexmedetomidine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine a... |
DB00414 | DB00443 | 590 | 251 | [
"DDInter16",
"DDInter195"
] | Acetohexamide | Betamethasone | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
590,
24,
251
]
],
[
[
590,
24,
870
],
[
870,
1,
251
]
],
[
[
590,
24,
1486
],
[
1486,
40,
251
]
],
[
[
590,
62,
1103
],
[
1103,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betamethasone (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone (Compoun... |
DB00222 | DB06595 | 245 | 1,491 | [
"DDInter825",
"DDInter1214"
] | Glimepiride | Midostaurin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
245,
24,
1491
]
],
[
[
245,
24,
1247
],
[
1247,
23,
1491
]
],
[
[
245,
24,
761
],
[
761,
24,
1491
]
],
[
[
245,
24,
1017
],
[
1017,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Saxaglip... |
DB00039 | DB11760 | 1,253 | 119 | [
"DDInter1380",
"DDInter1742"
] | Palifermin | Talazoparib | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1253,
24,
119
]
],
[
[
1253,
24,
599
],
[
599,
24,
119
]
],
[
[
1253,
24,
1619
],
[
1619,
63,
119
]
],
[
[
1253,
24,
1064
],
[
1064,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ruca... |
DB00704 | DB09052 | 267 | 250 | [
"DDInter1263",
"DDInter220"
] | Naltrexone | Blinatumomab | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
267,
24,
250
]
],
[
[
267,
24,
1412
],
[
1412,
63,
250
]
],
[
[
267,
24,
637
],
[
637,
24,
250
]
],
[
[
267,
63,
305
],
[
305,
2... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Asp... |
DB00013 | DB00584 | 1,255 | 610 | [
"DDInter1905",
"DDInter638"
] | Urokinase | Enalapril | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Moderate | 1 | [
[
[
1255,
24,
610
]
],
[
[
1255,
24,
743
],
[
743,
1,
610
]
],
[
[
1255,
24,
954
],
[
954,
40,
610
]
],
[
[
1255,
24,
714
],
[
714,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
[
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril (Compound) resembles Enalapril (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Enalapril (Compound)
Urokin... |
DB06603 | DB11979 | 39 | 1,320 | [
"DDInter1387",
"DDInter625"
] | Panobinostat | Elagolix | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
39,
24,
1320
]
],
[
[
39,
25,
1612
],
[
1612,
23,
1320
]
],
[
[
39,
25,
1297
],
[
1297,
24,
1320
]
],
[
[
39,
64,
79
],
[
79,
24... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostems... | Panobinostat may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Elagolix
Panobinostat may lead to a major life threatening interaction when taken with Osilodrostat and Osilodrostat may cause a moderat... |
DB08899 | DB12301 | 129 | 907 | [
"DDInter649",
"DDInter585"
] | Enzalutamide | Doravirine | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Major | 2 | [
[
[
129,
25,
907
]
],
[
[
129,
64,
1478
],
[
1478,
23,
907
]
],
[
[
129,
25,
159
],
[
159,
62,
907
]
],
[
[
129,
63,
392
],
[
392,
2... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doravirine"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u}... | Enzalutamide may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a minor i... |
DB00013 | DB00513 | 1,255 | 191 | [
"DDInter1905",
"DDInter70"
] | Urokinase | Aminocaproic acid | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. | Moderate | 1 | [
[
[
1255,
24,
191
]
],
[
[
1255,
24,
578
],
[
578,
62,
191
]
],
[
[
1255,
24,
848
],
[
848,
64,
213
],
[
213,
40,
191
]
],
[
[
1255,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminocaproic acid"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Aminocaproic acid
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibup... |
DB00877 | DB04908 | 629 | 1,671 | [
"DDInter1678",
"DDInter741"
] | Sirolimus | Flibanserin | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
629,
24,
1671
]
],
[
[
629,
24,
741
],
[
741,
63,
1671
]
],
[
[
629,
63,
303
],
[
303,
24,
1671
]
],
[
[
629,
24,
478
],
[
478,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone ac... |
DB00496 | DB00619 | 194 | 1,419 | [
"DDInter480",
"DDInter909"
] | Darifenacin | Imatinib | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
194,
24,
1419
]
],
[
[
194,
6,
12523
],
[
12523,
45,
1419
]
],
[
[
194,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
194,
63,
1101
],
[
110... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Darifenacin",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",... | Darifenacin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Imatinib (Compound)
Darifenacin (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and... |
DB00490 | DB00792 | 946 | 832 | [
"DDInter254",
"DDInter1878"
] | Buspirone | Tripelennamine | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
946,
24,
832
]
],
[
[
946,
24,
100
],
[
100,
63,
832
]
],
[
[
946,
25,
1264
],
[
1264,
63,
832
]
],
[
[
946,
24,
649
],
[
649,
1... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Buspirone may lead to a major life threatening interaction when taken with Doxepin and Doxepin may ... |
DB01232 | DB06605 | 1,327 | 1,409 | [
"DDInter1640",
"DDInter108"
] | Saquinavir | Apixaban | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
1327,
25,
1409
]
],
[
[
1327,
6,
3486
],
[
3486,
45,
1409
]
],
[
[
1327,
21,
29666
],
[
29666,
60,
1409
]
],
[
[
1327,
25,
1670
],
[
1... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Saquinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"... | Saquinavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Apixaban (Compound)
Saquinavir (Compound) causes Melaena (Side Effect) and Melaena (Side Effect) is caused by Apixaban (Compound)
Saquinavir may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a mode... |
DB06605 | DB11757 | 1,409 | 960 | [
"DDInter108",
"DDInter994"
] | Apixaban | Istradefylline | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Moderate | 1 | [
[
[
1409,
24,
960
]
],
[
[
1409,
63,
86
],
[
86,
24,
960
]
],
[
[
1409,
24,
971
],
[
971,
63,
960
]
],
[
[
1409,
24,
98
],
[
98,
24,... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilt... |
DB01138 | DB08895 | 804 | 976 | [
"DDInter1726",
"DDInter1825"
] | Sulfinpyrazone | Tofacitinib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
804,
24,
976
]
],
[
[
804,
24,
214
],
[
214,
63,
976
]
],
[
[
804,
63,
723
],
[
723,
24,
976
]
],
[
[
804,
40,
998
],
[
998,
24,... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepita... |
DB00679 | DB00902 | 684 | 104 | [
"DDInter1796",
"DDInter1168"
] | Thioridazine | Methdilazine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Major | 2 | [
[
[
684,
36,
104
]
],
[
[
684,
40,
11224
],
[
11224,
1,
104
]
],
[
[
684,
1,
11237
],
[
11237,
1,
104
]
],
[
[
684,
63,
13
],
[
13,
... | [
[
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Methdilazine"
]
],
[
[
"Thioridazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioproperazine"
],
[
"Thi... | Thioridazine (Compound) resembles Methdilazine (Compound) and
Thioridazine (Compound) resembles Thioproperazine (Compound) and Thioproperazine (Compound) resembles Methdilazine (Compound)
Thioridazine (Compound) resembles Acetophenazine (Compound) and Acetophenazine (Compound) resembles Methdilazine (Compound)
Thiorida... |
DB01099 | DB12615 | 1,272 | 1,381 | [
"DDInter744",
"DDInter1482"
] | Flucytosine | Plazomicin | A fluorinated cytosine analog that is used as an antifungal agent. | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Moderate | 1 | [
[
[
1272,
24,
1381
]
],
[
[
1272,
24,
416
],
[
416,
24,
1381
]
],
[
[
1272,
63,
361
],
[
361,
24,
1381
]
],
[
[
1272,
63,
1441
],
[
1441,
... | [
[
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
... | Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin... |
DB00238 | DB09098 | 188 | 98 | [
"DDInter1285",
"DDInter1700"
] | Nevirapine | Somatrem | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
188,
24,
98
]
],
[
[
188,
23,
608
],
[
608,
23,
98
]
],
[
[
188,
62,
168
],
[
168,
23,
98
]
],
[
[
188,
24,
159
],
[
159,
63,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"... | Nevirapine may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may c... |
DB00014 | DB01267 | 521 | 519 | [
"DDInter839",
"DDInter1381"
] | Goserelin | Paliperidone | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
521,
24,
519
]
],
[
[
521,
24,
1664
],
[
1664,
1,
519
]
],
[
[
521,
25,
924
],
[
924,
1,
519
]
],
[
[
521,
21,
29459
],
[
29459,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Goserelin may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Paliperidone (Compound)
Goserelin... |
DB01142 | DB01263 | 1,264 | 859 | [
"DDInter593",
"DDInter1494"
] | Doxepin | Posaconazole | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1264,
24,
859
]
],
[
[
1264,
6,
4973
],
[
4973,
45,
859
]
],
[
[
1264,
21,
28762
],
[
28762,
60,
859
]
],
[
[
1264,
62,
112
],
[
112,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Doxepin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Doxepin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazol... |
DB00754 | DB01234 | 157 | 1,220 | [
"DDInter696",
"DDInter513"
] | Ethotoin | Dexamethasone | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
157,
24,
1220
]
],
[
[
157,
63,
870
],
[
870,
1,
1220
]
],
[
[
157,
63,
175
],
[
175,
40,
1220
]
],
[
[
157,
24,
1486
],
[
1486,
... | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamet... |
DB01124 | DB01203 | 1,411 | 699 | [
"DDInter1828",
"DDInter1255"
] | Tolbutamide | Nadolol | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
1411,
24,
699
]
],
[
[
1411,
24,
729
],
[
729,
1,
699
]
],
[
[
1411,
63,
887
],
[
887,
1,
699
]
],
[
[
1411,
21,
28722
],
[
28722,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Nadolol (Compound)
Tolbutam... |
DB06605 | DB11730 | 1,409 | 351 | [
"DDInter108",
"DDInter1588"
] | Apixaban | Ribociclib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1409,
24,
351
]
],
[
[
1409,
63,
222
],
[
222,
23,
351
]
],
[
[
1409,
24,
283
],
[
283,
62,
351
]
],
[
[
1409,
63,
288
],
[
288,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib... |
DB05239 | DB08873 | 866 | 74 | [
"DDInter425",
"DDInter221"
] | Cobimetinib | Boceprevir | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Major | 2 | [
[
[
866,
25,
74
]
],
[
[
866,
24,
1374
],
[
1374,
23,
74
]
],
[
[
866,
63,
1424
],
[
1424,
24,
74
]
],
[
[
866,
64,
1220
],
[
1220,
... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abirate... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Boceprevir
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine... |
DB00960 | DB08907 | 887 | 1,344 | [
"DDInter1471",
"DDInter280"
] | Pindolol | Canagliflozin | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
887,
24,
1344
]
],
[
[
887,
24,
549
],
[
549,
1,
1344
]
],
[
[
887,
21,
28680
],
[
28680,
60,
1344
]
],
[
[
887,
63,
1486
],
[
1486,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Pindolol (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Canagliflozin (Compound)
Pindolol may cause a moderate interaction that... |
DB09291 | DB14575 | 741 | 733 | [
"DDInter1615",
"DDInter674"
] | Rolapitant | Eslicarbazepine | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
741,
24,
733
]
],
[
[
741,
63,
1101
],
[
1101,
23,
733
]
],
[
[
741,
63,
1264
],
[
1264,
24,
733
]
],
[
[
741,
62,
1135
],
[
1135,
... | [
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepi... |
DB01042 | DB14711 | 1,307 | 779 | [
"DDInter1144",
"DDInter1680"
] | Melphalan | Smallpox (Vaccinia) Vaccine, Live | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1307,
25,
779
]
],
[
[
1307,
64,
1064
],
[
1064,
25,
779
]
],
[
[
1307,
25,
1377
],
[
1377,
25,
779
]
],
[
[
1307,
63,
147
],
[
147,
... | [
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Clad... | Melphalan may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Melphalan may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a maj... |
DB11978 | DB15822 | 124 | 69 | [
"DDInter822",
"DDInter1504"
] | Glasdegib | Pralsetinib | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
124,
24,
69
]
],
[
[
124,
24,
283
],
[
283,
24,
69
]
],
[
[
124,
63,
1446
],
[
1446,
24,
69
]
],
[
[
124,
64,
985
],
[
985,
24,
... | [
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreot... |
DB00747 | DB09076 | 1,442 | 1,116 | [
"DDInter1647",
"DDInter1899"
] | Scopolamine | Umeclidinium | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
1442,
24,
1116
]
],
[
[
1442,
24,
849
],
[
849,
24,
1116
]
],
[
[
1442,
63,
1300
],
[
1300,
24,
1116
]
],
[
[
1442,
24,
337
],
[
337,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and H... |
DB00361 | DB00400 | 134 | 353 | [
"DDInter1939",
"DDInter843"
] | Vinorelbine | Griseofulvin | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Moderate | 1 | [
[
[
134,
24,
353
]
],
[
[
134,
6,
8374
],
[
8374,
45,
353
]
],
[
[
134,
21,
28745
],
[
28745,
60,
353
]
],
[
[
134,
63,
168
],
[
168,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Vinorelbine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Vinorelbine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound)
Vinorelbine (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Griseofulvin (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when... |
DB00029 | DB11703 | 25 | 405 | [
"DDInter99",
"DDInter9"
] | Anistreplase | Acalabrutinib | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
25,
25,
405
]
],
[
[
25,
24,
383
],
[
383,
24,
405
]
],
[
[
25,
24,
738
],
[
738,
63,
405
]
],
[
[
25,
25,
126
],
[
126,
25,
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken... |
DB04938 | DB08899 | 1,423 | 129 | [
"DDInter1353",
"DDInter649"
] | Ospemifene | Enzalutamide | Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1423,
24,
129
]
],
[
[
1423,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1423,
21,
28646
],
[
28646,
60,
129
]
],
[
[
1423,
63,
79
],
[
79,
... | [
[
[
"Ospemifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Ospemifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Ospemifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Ospemifene (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Enzalutamide (Compound)
Ospemifene may cause... |
DB00651 | DB09052 | 746 | 250 | [
"DDInter613",
"DDInter220"
] | Dyphylline | Blinatumomab | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
746,
24,
250
]
],
[
[
746,
40,
1031
],
[
1031,
24,
250
]
],
[
[
746,
24,
1317
],
[
1317,
24,
1412
],
[
1412,
63,
250
]
],
[
[
746,
... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Dyphylline",
"{u} (Compound) resembles {v} (Compound)",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a m... | Dyphylline (Compound) resembles Theophylline (Compound) and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may cause a moderate interaction ... |
DB00213 | DB06209 | 837 | 256 | [
"DDInter1388",
"DDInter1508"
] | Pantoprazole | Prasugrel | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Minor | 0 | [
[
[
837,
23,
256
]
],
[
[
837,
6,
10215
],
[
10215,
45,
256
]
],
[
[
837,
21,
28681
],
[
28681,
60,
256
]
],
[
[
837,
1,
1215
],
[
1215,
... | [
[
[
"Pantoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Pantoprazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound... | Pantoprazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Pantoprazole (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Pantoprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a minor... |
DB00054 | DB00472 | 1,432 | 758 | [
"DDInter6",
"DDInter758"
] | Abciximab | Fluoxetine | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
1432,
24,
758
]
],
[
[
1432,
24,
109
],
[
109,
40,
758
]
],
[
[
1432,
64,
20
],
[
20,
24,
758
]
],
[
[
1432,
25,
802
],
[
802,
6... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) resembles Fluoxetine (Compound)
Abciximab may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate d... |
DB00446 | DB11837 | 597 | 1,297 | [
"DDInter351",
"DDInter1351"
] | Chloramphenicol | Osilodrostat | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
597,
24,
1297
]
],
[
[
597,
25,
1135
],
[
1135,
23,
1297
]
],
[
[
597,
24,
112
],
[
112,
23,
1297
]
],
[
[
597,
23,
466
],
[
466,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
... | Chloramphenicol may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidaz... |
DB00196 | DB00867 | 600 | 1,052 | [
"DDInter743",
"DDInter1606"
] | Fluconazole | Ritodrine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Adrenergic beta-agonist used to control premature labor. | Moderate | 1 | [
[
[
600,
24,
1052
]
],
[
[
600,
24,
870
],
[
870,
23,
1052
]
],
[
[
600,
24,
1220
],
[
1220,
62,
1052
]
],
[
[
600,
24,
1148
],
[
1148,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Dexamethason... |
DB01030 | DB06636 | 869 | 1,623 | [
"DDInter1835",
"DDInter980"
] | Topotecan | Isavuconazonium | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
869,
24,
1623
]
],
[
[
869,
24,
466
],
[
466,
62,
1623
]
],
[
[
869,
63,
1419
],
[
1419,
24,
1623
]
],
[
[
869,
24,
309
],
[
309,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Ima... |
DB00023 | DB09079 | 305 | 1,496 | [
"DDInter127",
"DDInter1296"
] | Asparaginase Escherichia coli | Nintedanib | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
305,
24,
1496
]
],
[
[
305,
24,
707
],
[
707,
24,
1496
]
],
[
[
305,
24,
159
],
[
159,
63,
1496
]
],
[
[
305,
25,
990
],
[
990,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.